Skip to main content
. 2020 Oct 21;21(20):7802. doi: 10.3390/ijms21207802

Figure 3.

Figure 3

Leukotrienes type B4 production by MCF-7 (A) and MDA-MB-231 (B) cells, treated with ipilimumab mAb for 24 h, in the presence of human peripheral blood mononuclear cells (hPBMCs) under different condition (high glucose; low glucose; high glucose + empagliflozin at 50 nm; shifting from a high glucose to low glucose). Untreated or treated cells with an unrelated control IgG (control) were used as negative controls; (C) Leukotrienes type B4 production by AC-16 cells, treated with ipilimumab mAb for 24 h, in the presence of hPBMCs under different condition (high glucose; low glucose; high glucose + empagliflozin at 500 nM; shifting from a high glucose to low glucose). Untreated or treated cells with an unrelated control IgG (control) were used as negative controls. Error bars depict means ± SD (n = 3). Statistical analysis was performed using paired t-test. *** p < 0.001.** p < 0.01.* p < 0.05.